Cannabis Users Need Fewer Opioids After Surgery, Loma Linda Study Finds
Advertisement
A new study from Loma Linda University School of Medicine published in the Journal of Surgical Orthopaedic Advances has delivered findings that could reshape how clinicians think about post-operative pain management: patients who used marijuana required 94 fewer morphine milliequivalents for post-surgical pain control compared to non-users — while reporting comparable pain relief.
The study, published on March 11, 2026, examined 402 patients who underwent distal radius fracture fixation, a common surgical procedure to repair a broken wrist. Using a rigorous one-to-one propensity matching methodology, researchers compared outcomes between 35 marijuana users and a matched control group of non-users. The results suggest that cannabis use may play a role in reducing reliance on prescription opioids after surgery.
Key Takeaways
- The findings add to a growing body of 2026 research, including studies across nine million orthopedic procedures, supporting the opioid-sparing potential of cannabis.
- A Loma Linda University study found cannabis users required 94 fewer morphine milliequivalents after wrist fracture surgery while achieving comparable pain relief to non-users.
- While the study has limitations, particularly its small sample size of 35 marijuana users, it aligns with broader evidence that medical cannabis states see lower opioid prescription and overdose rates.
Table of Contents
- The Study in Detail
- Why This Matters: The Opioid Crisis Context
- Building on a Growing Evidence Base
- Limitations and the Path Forward
- What Patients Should Know
The Study in Detail
The Loma Linda research team focused on one of the most common orthopedic procedures: repair of a distal radius fracture, which accounts for approximately 18 percent of all fractures treated in emergency departments. The surgery involves stabilizing the broken bone with plates, screws, or pins, and post-operative pain management typically relies heavily on opioid prescriptions.
Of the 402 patients identified for inclusion in the study, 35 reported using marijuana. Researchers employed propensity score matching — a statistical technique that pairs participants based on similar baseline characteristics — to eliminate potential confounding variables such as age, gender, and injury severity.
The headline finding: marijuana users required 94 fewer morphine milliequivalents (MME) for post-operative pain management. Despite receiving substantially fewer opioids, these patients reported pain scores similar to those of non-users, suggesting they achieved comparable pain relief with significantly less reliance on prescription painkillers.
The study authors concluded that the findings "support further investigation into whether marijuana could help reduce opioid use following surgery, particularly as concerns over opioid dependence and overprescribing continue."
Why This Matters: The Opioid Crisis Context
The United States continues to grapple with an opioid epidemic that has claimed more than 500,000 lives since 1999, according to the Centers for Disease Control and Prevention. Surgical procedures remain one of the most common entry points for opioid exposure, with studies showing that approximately 6 percent of opioid-naive patients who receive post-surgical opioid prescriptions go on to develop long-term opioid use.
Reducing the opioid footprint of surgical recovery is a public health priority, and the Loma Linda study adds to a growing body of evidence suggesting that cannabis may serve as a viable opioid-sparing tool. A 94 MME reduction is clinically meaningful — roughly equivalent to eliminating 12 to 15 standard oxycodone pills from a patient's recovery regimen.
This matters beyond individual patient outcomes. States that have legalized medical marijuana have consistently shown lower rates of opioid prescriptions, opioid-related hospitalizations, and opioid overdose deaths compared to states without medical cannabis programs, according to multiple peer-reviewed analyses.
Building on a Growing Evidence Base
The Loma Linda study is not an isolated finding. It joins a rapidly expanding body of 2026 research exploring the relationship between cannabis use and opioid requirements in surgical and clinical settings.
A comprehensive review article published in Cureus in 2026 examined cannabis use across more than nine million orthopedic procedures — including total hip and knee arthroplasty, shoulder arthroplasty, spine fusion, and femur fixation. The analysis found that patients with documented marijuana use had lower in-hospital mortality than matched non-users, alongside reduced opioid consumption.
Meanwhile, a separate 2026 study published in the Journal of Pain Research found that CBD-dominant full-spectrum [Quick Definition: A product containing all naturally occurring cannabinoids, terpenes, and plant compounds] marijuana extracts were associated with stronger pain relief and fewer side effects than pure THC in older adults with chronic or treatment-resistant pain. The study compared two matched groups of 484 patients each over at least 24 weeks, with the CBD-dominant treatment producing greater benefits across every major category measured.
Additionally, a clinical trial examining balanced THC/CBD treatment for chronic temporomandibular disorder (TMJ) found a roughly 90 percent reduction in functional pain and significant improvement in jaw mobility — another data point suggesting cannabinoids can meaningfully address pain conditions traditionally managed with opioids.
Limitations and the Path Forward
The Loma Linda study has important limitations that researchers themselves acknowledge. The sample size of marijuana users (35 patients) is relatively small, and the study's retrospective design means it cannot establish a causal relationship between cannabis use and opioid reduction. Self-reported marijuana use may also introduce reporting bias, as patients may underreport cannabis consumption in clinical settings.
Additionally, the study does not distinguish between different types of cannabis use — whether patients consumed THC-dominant flower, CBD products, edibles, or concentrates — or quantify the frequency and dosage of their cannabis consumption. These variables likely influence pain management outcomes and represent important avenues for future research.
Despite these limitations, the study's use of propensity score matching strengthens its findings by controlling for observable differences between the two groups. And the consistency of its results with larger studies provides additional confidence in the direction of the findings.
Over 70 cannabis-related studies have been published in 2026 alone, spanning pain relief, cancer, brain injury, sleep, metabolism, inflammation, and wound healing. The volume of research underscores the urgency of moving from observational studies to large-scale randomized controlled trials that can definitively answer whether cannabis should be incorporated into post-surgical pain management protocols.
What Patients Should Know
For patients considering cannabis as part of their recovery, several practical considerations apply. First, cannabis is not a replacement for professional medical advice — any changes to a pain management plan should be discussed with a healthcare provider. Second, the legal landscape varies significantly by state, and patients should understand their local laws before incorporating cannabis into their recovery.
Third, the type of cannabis product matters. The broader research literature suggests that balanced THC/CBD formulations and CBD-dominant products may offer better pain relief with fewer side effects than high-THC products alone. Patients interested in exploring this option should seek guidance from healthcare providers experienced in cannabinoid medicine.
Finally, it is worth noting that the opioid-sparing potential of cannabis does not eliminate the need for opioids entirely. Some surgical recoveries will require prescription pain management regardless. The goal is harm reduction — using cannabis as a complementary tool to minimize opioid exposure, not to eliminate it altogether.
Pull-Quote Suggestions:
"The results suggest that cannabis use may play a role in reducing reliance on prescription opioids after surgery."
"A comprehensive review article published in Cureus in 2026 examined cannabis use across more than nine million orthopedic procedures — including total hip and knee arthroplasty, shoulder arthroplasty, spine fusion, and femur fixation."
"Finally, it is worth noting that the opioid-sparing potential of cannabis does not eliminate the need for opioids entirely."
Why It Matters: A new Loma Linda University study finds cannabis users required 94 fewer morphine milliequivalents after wrist surgery. Could marijuana reduce opioid dependence?